Sun Pharmaceutical Industries Ltd

NSE: SUNPHARMA · BSE: 524715 · Pharmaceuticals & Biotechnology · 54 announcements

Share price: ₹1,783.00
Market cap: ₹4,27,801 Cr
Revenue (annual): ₹58,462 Cr
Net profit (annual): ₹11,479 Cr
P/E (TTM): 35.4×Sector 47.4×
Promoter holding: 54.48%+0.00% QoQ
FII holding: 14.54%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

5 May 2026 23:16 IST NSE

Sun Pharmaceutical Industries Acquisition Worth ₹11,162 Cr

Sun Pharma announced the acquisition of Organon & Company for an enterprise value of $11.75 billion (approx. ₹1,11,625 Crore). The deal expands Sun's footprint in women's health and biosimilars across 140 countries, including a significant entry into China. The transaction is expected to close in six to nine months and be EPS accretive from the first year.

Value: ₹11,162 Cr
Execution: 6 to 9 months

Read the filing ↗

27 Apr 2026 18:58 IST NSE

Acquisition

Sun Pharmaceutical Industries Acquisition Worth ₹37,649 Cr

Sun Pharmaceutical's US subsidiary will acquire 100% of Organon & Co. for ₹37,649 Crore ($3.99B equity value) in an all-cash merger. The deal, valued at $11.75B enterprise value, strengthens Sun's global portfolio in women's health and biosimilars. Completion is expected in early 2027, subject to regulatory and shareholder approvals.

Value: ₹37,649 Cr
Execution: Early 2027

Read the filing ↗

27 Apr 2026 05:23 IST NSE

Acquisition

Sun Pharmaceutical Industries Acquisition Worth ₹110,450 Cr

Sun Pharma has agreed to acquire 100% of Organon & Co. for US$ 14.00 per share in an all-cash deal valued at ₹110,450 Crore (EV). The acquisition marks Sun Pharma's entry into biosimilars and significantly expands its global Women's Health portfolio. The transaction is expected to close in early 2027.

Value: ₹1,10,450 Cr
Execution: Early 2027

Read the filing ↗